Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

@article{Pasquinelli2012SingleAM,
  title={Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.},
  author={Claudio Pasquinelli and Fiona Mcphee and Timothy Eley and Criselda Villegas and Katrina Sandy and Pamela L Sheridan and Anna Persson and Shu-Pang Huang and Dennis Hernandez and Amy K Sheaffer and Paul M Scola and Thomas C. Marbury and Eric J. Lawitz and Ronald Goldwater and Maribel Rodr{\'i}guez-Torres and Michael P Demicco and David Wright and Michael Charlton and Walter K Kraft and Juan-Carlos Lopez-Talavera and Dennis M. Grasela},
  journal={Antimicrobial agents and chemotherapy},
  year={2012},
  volume={56 4},
  pages={1838-44}
}
Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…